Apply to join the ENABLE-2 consortium

ENABLE-2 is accepting molecules with direct acting systemic antibacterial activity and a novel mode of action targeting the ESKAPE pathogens: carbapenem-resistant EnterobacteriaceaeP. aeruginosa, A. baumannii; methicillin-resistant S. aureus; vancomycin-resistant E. faecium.

How to apply to ENABLE-2

Please note The ENABLE-2 programme is currently full. Future calls will be announced on this webpage, check in regularly for updates.

The ENABLE-2 platform offers further development of Hits up to a level of advancement where they can successfully graduate to later stage initiatives (e.g., CARB-X, GARDP, REPAIR Impact Fund) or to out-licensing.

Novel modes of action can include action at a novel target, a novel mechanism of action against a known target, or a known mechanism of action against a known target so long as there is demonstrated activity against target-based resistant strains and management of known liabilities is appropriate.


Academics and SMEs within Sweden are eligible to submit a three-page Expression of Interest (EoI) to the ENABLE-2 platform with details of their anti-bacterial programme. SMEs receiving a positive evaluation from the PMC, and after completion of a description of work (DoW) with input from the ENABLE-2 management team will have the opportunity to apply for funding from VINNOVA.

Please note: Swedish SMEs can after a positive evaluation from the ENABLE-2 PMC apply for funding from Vinnova for further development according to the plans laid out in the DoW. Vinnova can fund a maximum of 70% of the costs estimated by the DoW. The ENABLE-2 management team will give more detailed information to these SMEs on how to proceed when relevant.


Molecules/series with a novel mode of action targeting in-scope pathogens

  • direct acting small molecules and natural products for systemic activity
  • potentiation effect possible (eg beta-lactamase inhibitors)
  • activity against resistant clinical strains
  • single pathogen spectrum possible

Minimum inhibitory concentration (MIC) ≤ 16 μg/mL vs. at least one of the key ENABLE-2 pathogens

  • E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus, E. faecium
  • specific antibacterial activities (activities not due to broad cytotoxicity)

Potential for optimization

  • proven chemical structure and preliminary Structure–Activity Relationship
  • reasonable route of synthesis (or proven availability if a Natural Product)
  • favorable chemical properties allowing iv and/or oral administration
  • clear legal/IP situation

If the scientists do not have a Hit compound meeting the criteria for entry into ENABLE-2 but do have a good scientific rational for a target or potential Hit compound they will have the opportunity to apply for support from SciLifeLab (Drug Discovery and Development Platform (DDD) or the Chemical Biology Consortium Sweden, CBCS) to further develop such a compound.

Please contact SciLifeLab DDD for more information concerning these applications.

Download EoI template

​After you submit your EoI


Anders Karlén, Coordinator, Professor
Uppsala University (SE), +46 (0)70-167 9177 

Last modified: 2022-05-19